1. Generics Bulletin
  2. >>Products

Hikma Differentiates With Succinylcholine Chloride PFS

Represents First Pre-Filled Syringe Formulation Version Launched In US

 
• By Dave Wallace

Hikma has debuted a pre-filled syringe formulation of succinylcholine chloride in the US, representing the first FDA-approved PFS version of the product to be launched in the market.

Hikma logo on phone, binary code in background
Hikma has launched the first pre-filled syringe formulation of succinylcholine chloride • Source: Shutterstock

Hikma has launched the first US Food and Drug Administration-approved pre-filled syringe version of succinylcholine chloride in the US, differentiating itself against the multiple versions of the 20mg/ml injectable already present in the US market.

“The 100mg/5ml PFS has been launched in the US and is the first FDA-approved PFS for this product to be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By Vibha Ravi

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment.

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By Dave Wallace

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Where Art Thou Celltrion? Kabi Pushes Past With US Denosumab Launches

 
• By Dean Rudge

Fresenius Kabi has become the second company to launch US denosumab biosimilars, taking its current biosimilars portfolio up to six products.

‘America Leans On Hikma’ And Its $1bn Domestic Drug Manufacturing Investment

 
• By Urtė Fultinavičiūtė

Claiming to be a top-three supplier of sterile injectables in the US, Hikma intends to invest $1bn over the next five years to further expand its American manufacturing base, as the threat of tariffs still looms.

More from Generics Bulletin

One Month Remains To Enter GGB Awards 2025

 
• By Dave Wallace

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.

Advanz Claims Cimzia Biosimilar In Europe Following Alvotech-Xbrane Deal

 
• By Dean Rudge

A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.

Biocon Biologics’ Yesafili Approved And Ready To Launch In Canada

 
• By Urtė Fultinavičiūtė

Canada will welcome its first Eylea off-patent rival in July, as Biocon Biologics celebrates the commercialization of its 10th biosimilar worldwide.